Navigation Links
OraVerse (R) Selected by Dentistry Today Magazine as One of the Top 100 Products of 2009
Date:7/14/2009

SAN DIEGO, July 14 /PRNewswire/ -- Novalar Pharmaceuticals, Inc., a dental specialty pharmaceutical company today announced that OraVerse(R), the company's premier dental pharmaceutical product, has been selected by leading dental industry magazine Dentistry Today as one of its Top 100 Products for 2009. The full results of the 23rd annual competition were published in the July issue.

OraVerse is the first and only local anesthesia reversal agent that accelerates the return to normal sensation and function for patients who want to avoid the unwanted and unnecessary lingering soft tissue anesthesia following routine dental procedures. The first-in-class product was officially launched earlier this year and is currently available to dentists through Novalar's direct pharmaceutical sales force.

"We have been using OraVerse for several months now and feel it is an excellent service for many of our patients. It fits well with our goal of enhancing the overall patient experience," said leading cosmetic dentist Stephen Glassman, DDS of Glassman Dental Care in New York City. "Our patients are very enthusiastic about the results and are excited to get back to work and get on with their day," he added.

Dentistry Today noted that the Top 100 Products are selected on the basis of reader response and represent what's new and innovative in the dental profession. Clinical data for OraVerse has also been published in a number of leading peer reviewed scientific journals including the nation's leading dental publication, the Journal of the American Dental Association.

OraVerse comes in a standard dental cartridge and is easily injected utilizing the same injection site and an identical technique as that used for local anesthetic. It is used in a 1:1 ratio to local anesthetic and has been tested in doses of 1/2, 1 and 2 cartridges. For more information or
'/>"/>

SOURCE Novalar Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Video: Novalar Announces the Launch of OraVerse(TM) the First Dental Anesthesia Reversal Agent
2. Novalar Receives FDA Approval for OraVerse(TM)
3. Perot Systems Selected to Implement Health Information Systems in China
4. TrainingPeaks Selected As "Official Training Software" Of Bike MS And Joe Friel Selected As The "Official Coach"
5. Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn
6. Two Flight Surgeons Supporting Wyles Bioastronautics Contract Selected for New Astronaut Class
7. China Medical Technologies Announces Selected Unaudited Preliminary Financial Results for the Fourth Fiscal Quarter and Full Year Ended March 31, 2009
8. iMedica Selected by NJ Physicians as Preferred EHR Vendor
9. Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation
10. 17 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences
11. Meridios, Ltd Selected as a Nationwide CMS Qualified Registry to Report Healthcare Quality Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 29, 2014 The Global and China ... the current state of the Oscilloscope industry in Global ... of the industry, including definitions, applications and industry chain ... are provided with a focus on history, developments, trends ... the international and Chinese situation is also offered. , ...
(Date:8/28/2014)... Top10BestSEOHosting.com has recently compared many professional web ... Bluehost are the best hosting suppliers in 2014. ... in the hosting industry for more than 13 ... GB connections to ensure that there would be ... The great thing is that all hosted websites ...
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... promote National Recovery Month throughout September. This month ... of addiction treatment and mental health services. Along ... Millennium Treatment Group is helping to spread the ... Month began in 1989, honoring the work of ...
(Date:8/28/2014)... TN (PRWEB) August 28, 2014 American ... insurance industry on the Internet will now have a ... Pros company. In one click this year, some of ... at http://quotespros.com/life-insurance.html . , The promoted plans ... Quotes Pros finder tool represent popular policies. The term, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ABC television ... the 49th MDA Show of Strength Telethon airing Sunday, ... country to help raise funds and awareness to help ... affected by muscle disease. , Viewers tuning into the ... enjoy heart-felt appeals and introductions from some of the ...
Breaking Medicine News(10 mins):Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 2Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 3Health News:Best Suppliers of Affordable Hosting Products Introduced by Top10BestSEOHosting.com 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4
... Neuisys Imaging System,Solutions, LLC announced today that the U.S. ... the NeuViz 16 Multi-Slice Computed,Tomography (CT) System. The NeuViz ... venture between Royal Philips Electronics of the Netherlands,and Neusoft ... NeuViz 16 is a state-of-the-art CT system that provides ...
... hypertension during pregnancy, Marshal D. Lindheimer, MD, professor emeritus ... Medicine and in the Committee on Clinical Pharmacology and ... 2009 Joseph Bolivar DeLee Humanitarian Award from the Board ... University of Chicago Medical Center. , The ...
... Accounting Related to Two Transactions , PHOENIX, Feb. 23 ... in stabilized rice bran (SRB) nutrient research and technology, ... recommendations of the Audit Committee of its Board of ... fiscal year ended December 31, 2007. This includes the ...
... 23 HealthyPlace.com , which provides the most extensive ... the internet, unveils several important new features for those ... features HealthyPlace Mediminder , a free medication reminder ... them to take their medication or refill their prescription. ...
... Fiber Bring Great Taste and Digestive Health Benefits to ... Company, Inc., announced today that it will expand the ... probiotic portfolio. Both cultured fresh dairy products, Activia Dairy ... the same scientifically proven benefits of all Activia products, ...
... say yes, but American experts aren,t so sure , , ... Taiwan links aggression in teens to heavy Internet use, ... , The research, based on questionnaires about Internet ... percent of the boys and 13 percent of the girls ...
Cached Medicine News:Health News:Neuisys Announces FDA Clearance of NeuViz 16 Multi-Slice CT System 2Health News:2009 DeLee Humanitarian Award goes to Marshall Lindheimer, M.D., of the University of Chicago 2Health News:2009 DeLee Humanitarian Award goes to Marshall Lindheimer, M.D., of the University of Chicago 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 2Health News:NutraCea to Restate Financial Statements for 2007 and 2008 3Health News:NutraCea to Restate Financial Statements for 2007 and 2008 4Health News:NutraCea to Restate Financial Statements for 2007 and 2008 5Health News:HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder 2Health News:HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder 3Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 2Health News:Dannon(TM) Expands Probiotic Portfolio with New Activia(TM) Extensions 3Health News:Are Internet-Addicted Kids More Violent? 2
(Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets ... Target High Unmet Need in Newly ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... SAN DIEGO , Aug. 28, 2014 ... drug development company that merged with MabVax Therapeutics, ... has made significant progress related to the development ... fully-human antibody was recovered using the Company,s internally ... demonstrate the potential for multiple antibody based therapeutic ...
(Date:8/28/2014)... , Aug. 28, 2014 Amgen (NASDAQ: ... Biologics License Application (BLA) to the U.S. Food and ... treatment of high cholesterol. Evolocumab is an investigational fully ... 9 (PCSK9), a protein that reduces the liver,s ability ... from the blood. 1 ­ ...
Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... largest Phase 3 study conducted in MDS - Vidaza therapy confers ... survival advantage compared to conventional care regimens, - Two year overall survival ... ... Colo., Jan. 14 Pharmion Corporation,(Nasdaq: PHRM ) today announced the ...
... CEL-SCI Corporation,(Amex: CVM ) reports financial results ... reports a net operating loss for fiscal year 2007 ... fiscal year 2006. The loss per,share for fiscal year ... The cash from operating activities used during the ...
Cached Medicine Technology:Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7CEL-SCI Corporation Announces 2007 Financial Results 2CEL-SCI Corporation Announces 2007 Financial Results 3
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
...
Gentamicin Sulphate : Antibiotic that inhibits normal protein synthesis. USBio analysed. Autoclavable....
Medicine Products: